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Abstract
Background: Cryptosporidium is among the most common causes of severe diarrhea in African children 0–23
months old. It is associated with excess mortality, stunting and malnutrition. The most common manifestation
of cryptosporidium is intestinal diarrheal disease. However, respiratory cryptosporidiosis has been documented
in up to a third of children presenting with diarrhea. It is unclear whether respiratory involvement is a transient
phenomenon or a reservoir for gastrointestinal (GI) disease. This study aims to evaluate the role of respiratory
cryptosporidiosis in pediatric diarrheal disease.
Methods: This is a prospective, observational study conducted at Queen Elizabeth Central Hospital (QECH) in
Blantyre, Malawi. Young children aged 2–24months hospitalized with diarrhea will be enrolled. Enrolled children
will have induced sputum, nasopharyngeal (NP) swab and stool samples collected. All participants positive for
cryptosporidium on sputum/NP/stool PCR testing will be followed up fortnightly after discharge from the hospital
up to 8 weeks post-discharge. Sputum/NP/stool sample collection will be done at each visit. The primary outcomes
will be presence of Cryptosporidium spp. in sputum/NP/stool. The secondary outcome will be presence of respiratory
and GI symptoms, mortality and stunting. Ethical approval was obtained from the University of Malawi College of
Medicine Research Ethics Committee (COMREC) and the Liverpool School of Tropical Medicine (LSTM) research ethics
committee.
Discussion: The study began recruitment activities at QECH in February 2019. The protocol allows for expansion of
recruitment to secondary sites within Blantyre and Chikwawa districts in the event that targets are not met at QECH.
Study recruitment is expected to continue until early 2020.
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Background
Cryptosporidiosis is a cause of severe diarrhea [1], excess
mortality [2, 3], and stunting, and is associated with
malnutrition [4]. The Global Enteric Study (GEMS) identi-
fied Cryptosporidium as the second most common cause of
diarrhea among infants (0–11months) in all four African
countries studied (The Gambia, Mali, Mozambique and
Kenya) regardless of HIV prevalence, and among the top
five causes for older children (12–23months) [2]. The
Etiology, Risk Factors and Interactions of Enteric Infections
and Malnutrition and the Consequences for Child Health
and Development Program (MAL-ED) noted that crypto-
sporidiosis is the fifth highest attributable pathogen in all
pediatric diarrhea in the community setting, and has
increased frequency among those with prolonged and
severe diarrhea [1]. Cryptosporidiosis is associated with
excess mortality in children who had the infection in in-
fancy, and this excess mortality persists into the second year
of life. Respiratory cryptosporidiosis has been documented
in up to a third of children presenting with diarrhea [5];
furthermore, respiratory detection without intestinal
involvement has been reported, raising the possibility of
primary respiratory infection with Cryptosporidium spp.,
either by inhalation or by contact with fomites [6].
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Malawi has a high prevalence of Cryptosporidium. In a
recent case control study of children who presented with
diarrhea (≥ 3 loose stools within a 24 h period) to
QECH, Cryptosporidium spp. (27.8%) was the third most
common pathogen detected behind rotavirus (34.7%)
and adenovirus (29.1%) among cases [7]. This is much
higher than previous reports likely due to improved
diagnosis using molecular methods (PCR) [7, 8]. The
rainy season is associated with higher incidence of dis-
ease compared to the dry season but a study comparing
Blantyre (urban) to Chikwawa (rural) did not show a
significant difference in number of cases between urban
and rural dwellers [8].
Rationale
Studies have identified Cryptosporidium spp. in spu-
tum but have not looked at whether respiratory in-
volvement is a transient phenomenon or a reservoir
for gastrointestinal (GI) disease. Our study is unique
in that this is the first longitudinal study to evaluate
for pulmonary and GI Cryptosporidium concurrently.
If respiratory cryptosporidiosis is established to be a
reservoir for diarrheal disease, findings would inform
the development of systemic therapeutic interventions
against Cryptosporidium.
The main study hypothesis is that pulmonary Crypto-
sporidium can be a nidus of infection for Cryptosporid-
ium. Secondly, we hypothesize that pulmonary and GI
Cryptosporidium will lead to worse outcomes (mortality,
stunting) than those with only GI Cryptosporidium.
Study objectives
Primary objectives
The primary objectives are: (1) To estimate the propor-
tion of young children on admission hospitalized with
Cryptosporidium diarrhea that have Cryptosporidium
detected from the respiratory tract; and (2) To evaluate
the longitudinal pattern of pulmonary cryptosporidiosis
in children hospitalized with Cryptosporidium diarrhea.
Secondary objectives
The secondary objectives are: (1) To identify risk factors
for respiratory cryptosporidiosis in children with diar-
rhea; (2) To determine the proportion of children with
diarrhea and with Cryptosporidium in the respiratory
tract that have associated respiratory symptoms; and (3)
To determine the detection rate of Cryptosporidium in
the GI and respiratory tract, and longitudinally, detec-
tion in one tract or the other and the relationship to
respiratory and GI symptoms.
Primary outcomes
The presence of Cryptosporidium spp. in sputum/NP
swab and stool.
Secondary outcomes
The presence of respiratory and GI symptoms, mortality
and stunting.
Methods/design
Study type
This prospective, observational and longitudinal study
will evaluate the role of respiratory cryptosporidiosis in
pediatric diarrheal disease.
Study location
The primary site for this study is QECH located in
Blantyre, Malawi. Subjects will be recruited from the
Pediatric Accident and Emergency and pediatric wards
at QECH. If recruitment targets are not met at QECH,
recruitment will be expanded to secondary sites includ-
ing Blantyre District Health Office health centers and
Chikwawa District Hospital in Chikwawa, Malawi.
Study population
Young children 2–24months of age hospitalized with a
primary diagnosis of diarrhea will be enrolled into the
study, provided parents/ guardians complete the informed
consent process and children fulfill all the inclusion and
exclusion criteria.
Inclusion criteria
 Male or female
 Age 2–24 months
 Hospitalized with diarrhea (defined as 3 or more
loose stools within 24 h)
 Lives within 15 km radius of Blantyre district
 Positive on sputum/NP swab or stool for
Cryptosporidium by PCR
 Parent/guardian consent for enrollment
Exclusion criteria
 Dysentery (visible blood in loose stool)
Study procedures
Recruitment
Persons screened for study entry will be those presenting
with primary GI symptoms to QECH and/or health
centers in Blantyre or Chikwawa region, and who are
eligible for hospitalization. Eligible patients meet all the
inclusion and none of the exclusion criteria.
Subjects for this study will be recruited from the study
site by word of mouth. Patients attending clinics other
than health centers or district hospitals with inpatient
facilities will be informed about the study at Triage.
Before any study related activities, the study team will
obtain informed consent.
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Screening
Following admission and after obtaining informed con-
sent, an electronic folder will be created on tablet com-
puters for potential participants. Data collected will
include demographic information, medical history, phys-
ical examination and results of relevant investigations
performed as part of routine care (including full blood
count (FBC), urea and electrolytes (U&E), and liver func-
tion tests (LFTs), malaria parasite screen, blood and/or
CSF culture, TB GeneXpert and acid fast bacilli (AFB)
testing). All HIV exposed infants will have HIV DNA PCR
done.
All enrolled patients will have induced sputum/NP
swab and stool samples collected. Induced sputum will
only be collected if there are no contraindications
(based on PERCH criteria for induced sputum collec-
tion): severe hypoxia < 92% on supplemental oxygen;
inability to protect airways; severe bronchospasm at
admission (defined as continued hypoxia < 92% after
appropriate bronchodilator therapy, with other markers
of respiratory distress); seizure within the past 24 h;
deemed inappropriate by the clinician for another rea-
son (e.g. midface trauma, inhalational injury, pulmonary
effusion, congestive heart failure, congenital heart dis-
ease, etc.). If the above symptoms/conditions resolve
during the hospital course, induced sputum collection
may be reconsidered at that point.
Sampling procedures
The induced sputum procedure will be as follows.
Subjects will be given a nebulized β-agonist (salbutamol)
followed by 3% sodium chloride mist to inhale for 5–15
min. A sterile catheter will then be passed through the
nose into the posterior nasopharynx and suction applied
to aspirate contents. If the child does not tolerate the
procedure or has an adverse reaction, the procedure will
be discontinued and the child will be monitored up to 4
h post procedure. Once stabilized, and parents are amen-
able, the induced sputum collection can be attempted 24 h
later.
Quality of sputum will be documented by microscopy
(good quality: ≤10 squamous epithelial cells/low pow-
ered field). The first 100 subjects screened will also have
NP swab collected in addition to induced sputum, in
order to compare the yield of Cryptosporidium detection
between these two specimen types. If the yield is deemed
equivalent, subsequent respiratory tract sampling after
the first 100 subjects will include only NP swabs. All
sputum and stool specimens from recruited subjects will
also be subjected to multiplex testing for multiple patho-
gens but the results will not be returned by enrollment.
If the patient remains hospitalized for longer than a
week then sputum/NP swabs and stool samples will be
collected weekly until discharge. With each sample col-
lection, the patients will be assessed for symptoms and
results from relevant laboratory investigations performed
as part of routine care will be recorded. At discharge,
the patients will be assessed for symptoms but no speci-
mens will be collected.
Enrollment and follow-up
Participants that are positive for Cryptosporidium on
NP/sputum/stool testing will continue to be followed up
in the study (Table 1). They will be instructed to return
to the clinic for a follow-up visit fortnightly for evalu-
ation of symptoms, physical assessment, as well as spu-
tum/NP and stool sampling. A final follow up visit will
be scheduled approximately 8 weeks after discharge for
final evaluation of symptoms, physical assessment, and
sputum/NP and stool sampling. Table 2 provides an
overview of all study visits and scheduled study events.
Laboratory processing
HIV testing
All participating children will be tested for HIV on admis-
sion by QECH HIV testing counselors. These are part of
routine care and so will enhance the management of these
individuals. In line with national guidelines, HIV testing
will be with 2 complementary rapid tests (UniGold™ and
Determine™) according to manufacturers’ instructions. As
HIV antibody testing is not a reliable marker of HIV status
in infants until about 18months of age, we will perform
Table 1 Overview of study visits
Visit Activities
1 Admission to the inpatient ward,
assessment, collection of induced
sputum and stool sample
1a. If sputum/NP/stool is positive
for Cryptosporidium, continue to
follow
1b. If sputum/NP/stool is negative
for Cryptosporidium, discontinue
from study
If the patient remains hospitalized
for longer than 2 weeks then sputum/
NP swab and stool samples will be
collected fortnightly until discharge.
2 Outpatient Week 2 follow-up visit,
assessment, collection of induced
sputum/NP swab and stool sample
3 Outpatient Week 4 follow-up visit,
assessment, collection of induced
sputum/NP swab and stool sample
4 Outpatient Week 6 follow-up visit,
assessment, collection of induced
sputum/NP swab and stool sample
5 Outpatient Week 8 follow-up visit,
assessment, collection of induced
sputum/NP swab and stool sample
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HIV DNA PCR testing on all recruited children < 18
months with a positive HIV test.
Induced sputum and stool processing
Induced sputum collection will be done in a well-venti-
lated room (at QECH, this will be a patient procedure
room in the Paediatric Research Ward) equipped with an
emergency tray. Quality of the sputum will be docu-
mented by microscopy. All participating children will have
admission sputum and stool specimens evaluated for
Cryptosporidium, by Cryptosporidium PCR for sputum or
the TaqMan assay for stool, in batched testing. Only the
admission specimens that are positive for Cryptosporid-
ium in either sputum or stool will have all subsequent
specimens processed for multiplex testing. Multiplex test-
ing on sputum will test for bacteria (S. pneumoniae, S.
aureus, M. catarrhalis, B. pertussis, H. influenzae and H.
influenzae type b, C. pneumoniae, M. pneumoniae, K.
pneumoniae, L. pneumophila, and Salmonella species);
viruses (influenza A/B/C, RSV A/B, parainfluenza virus
types 1–4, coronaviruses NL63, 229E, OC43, and HKU1,
human metapneumovirus A/B, rhinovirus, adenovirus, en-
terovirus, parechovirus, bocavirus, cytomegalovirus); and
parasites (P. jirovecii). Multiplex testing of stool will test
for viruses (rotavirus, norovirus GII, adenovirus, astro-
virus, sapovirus), bacteria (enterotoxigenic Escherichia coli
(ETEC), enteropathogenic E. coli (EPEC), enteroaggrega-
tive E. coli (EAEC), Shiga-toxigenic E. coli (STEC),
Shigella/enteroinvasive E. coli, Salmonella, Campylobacter
jejuni, C. coli, Vibrio cholerae, Clostridium difficile), and
parasites (Cryptosporidium, Giardia lamblia, Entamoeba
histolytica, Ascaris lumbricoides, and Trichuris trichiura).
Statistical analysis
Sample size
About 250 subjects will be screened. Various studies
identified Cryptosporidium diarrhea in 12.5–13.8% of
children [2, 5]. Therefore, with a sample size of 250 chil-
dren, we anticipate 30–35 to have positive stool samples
at admission.
Analysis
The primary endpoints (detection of Cryptosporidium in
stool, sputum) are binary. Frequencies and proportions of
observed levels will be reported for binary and categorical
variables, with exact binomial 95% confidence intervals
given where appropriate. For all continuous variables we
will report the population size, the non-missing sample
size, the mean, and standard deviation, median, minimum,
maximum and interquartile range. Age distribution will be
reported as a categorical variable with age bands defined
as 2–11months and 12–24months.
Based on a planned sample size of 250 children, to es-
timate proportions we expect to achieve the absolute
margins of error given in Table 3 for different values of
proportions and sample sizes of children hospitalized
with Cryptosporidium diarrhea.
For Objective 1a, based on the Mor et al. paper we ex-
pect 14.7–35.4% of recruited subjects with diarrhea to
have Cryptosporidium in stool and sputum at admission
Table 2 Summary of study events schedule
Study event Study day/Interval
Inpatient Outpatient visits
(Week post-discharge)
Admission Every 2 weeks Discharge 2 4 6 8
Informed consent X
Inclusion/exclusion criteria X
Demographics X
Medical history X X X X X X X
Vital signs X X X X X X X
Physical exam X X X X X X X
HIV rapid test +/− HIV DNA PCRa X
Relevant investigations
(e.g. CXR, FBC, blood culture, etc.)
+/− Only if clinically indicated
Induced sputum for microscopy,
Cryptosporidium qPCR, and multiplex testing
X X Xb Xb Xb Xb
NP swab for Cryptosporidium qPCR for first
100 subjects only
X X Xb Xb Xb Xb
Stool for TaqMan array X X Xb Xb Xb Xb
aWill be performed on all infants < 18 months who are positive on rapid HIV test
bSubset of those positive on sputum/NP swab or stool for Cryptosporidium PCR on admission
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(4–12 sputum-positive out of a total of 35 stool-
positive).
For Objective 1b, we expect the proportion to be
higher. If the estimated proportion is 35% and we esti-
mate this proportion from n = 30 children hospitalized
with Cryptosporidium diarrhea, then we can estimate
this proportion with an absolute margin of error of 18%
(exact binomial 95% confidence interval [17, 53%]).
For Objective 2, we do not have an expected estimate as
our study will be the first to look at this. However, Table 3
gives a range of proportions between 15 and 50%.
Time to subsequent detection in the respiratory tract
or GI tract will be evaluated using time-to-event analysis
methods for interval-censored data. Specifically, we will
use non-parametric maximum likelihood estimators and
generalized log-rank tests for unadjusted analyses and
Cox regression for adjusted analyses.
Comparisons between groups of patients (defined by age
band, HIV status, etc.) will be performed using the exact
Fisher test for binary and categorical variables, t-test (two
groups) or ANOVA (three or more groups) for approxi-
mately normally distributed variables and Wilcoxon rank
sum (2 groups) or Kruskal-Wallis (3 or more groups) tests
for variables with severely non-normal distributions. To
evaluate outcomes longitudinally we will use mixed models
for data with patient ID treated as a random factor.
Data safety and monitoring
Data will be collected onto standard proformas and all
records will be held securely in MLW project offices.
Proformas will be destroyed after 10 years. Each study
participant will be assigned a unique study number at
enrolment. Demographics and relevant medical history
will be collected on a structured case record form (CRF)
that will be electronically captured (ODK system) and
stored on a password-protected database. Data files
(anonymized) will be exported to Stata (Statacorp, USA)
for analysis.
All data will be acquired and validated by the MLW
data team. All databases will be protected by passwords.
The only sources of person-identifiable information will
be the consent form, enrollment log, and the participant
tracking form. The latter will detail the subjects’ name,
contact details and the unique study number, in order to
provide a link with the anonymized clinical data. The
paper copy will be kept in a secured locked cabinet held
separately from the CRF hard copies. The electronic
copy will be stored in a password-protected database.
Only authorized study personnel will have access to this
information.
The study will be monitored by an internal monitoring
committee, Malawi-Liverpool Wellcome Trust (MLW)
Clinical Research Support Unit (CRSU) and the University
of Malawi College of Medicine Research and Ethics
Committee (COMREC).
Ethical considerations
This study protocol and informed consent documents
were reviewed and approved by COMREC protocol
number: P.07/18/2438 and the Liverpool School of
Tropical Medicine Research Ethics Committee (LSTM
REC protocol number: 18–066). For the purposes of this
study, COMREC will be considered the local IRB and
LSTM REC the remote IRB.
Recruitment
Subjects for this study will be recruited from the study site
by word of mouth. Patients attending clinics other than
health centers or district hospitals with inpatient facilities
will be informed about the study at triage. A poster will be
placed at each clinic announcing the study. All study pro-
cedures will be performed at QECH, health centers or
district hospitals with inpatient facilities.
After meeting inclusion/exclusion criteria and providing
documented informed consent forms (ICF), subjects will be
screened using a PCR for the presence of Cryptosporidium
infection. Subjects testing positive for Cryptosporidium
infection will continue participation in the longitudinal
phase of the study. The longitudinal phase of the study will
be explained and discussed with the subject at the time of
enrollment, and will be reviewed with the patient if they
test positive.
Informed consent process
Young children will be recruited. Before any study-related
activities and in agreement with applicable regulatory
Table 3 Absolute margins of error for different values of proportions and sample sizes of children hospitalized with
Cryptosporidium diarrhea, based on a sample size of 250
Proportion of
children with
Crypto diarrhea (%)
Number of
children with
Crypto diarrhea
Proportion of children hospitalized with Cryptosporidium diarrhea with a positive sputum test (%)
15 20 25 30 35 40 45 50
10 25 15.77 16.94 17.89 19.28 19.75 20.10 20.33 20.45
12 30 13.48 15.43 16.80 17.33 17.76 18.37 18.67 18.70
14 35 12.73 14.25 15.38 16.22 16.54 17.01 17.26 17.31
16 40 12.06 13.30 14.25 14.98 15.53 15.90 16.13 16.20
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requirements, the Investigator will ensure that the subject
and parent/guardian is fully informed about the aims, pro-
cedures, potential risks, and potential benefits of the study.
The subject’s parent/guardian will be given the written,
IRB-approved ICF, allowed ample time to read the con-
sent form, allowed to ask questions about the study, have
their questions answered and then be given time to decide
if s/he would like her child to participate in the study. It
will be emphasized that participation is voluntary, and that
the subject has the right to withdraw from the study at
any time without prejudice.
For enrollment into the study, the subject’s parent/
guardian will need to sign an ICF. The Investigator will
obtain the parent/guardian’s voluntary, personally signed
and dated ICF before any study-related procedure can be
conducted. The original, signed ICF(s) will be kept in the
site study file. Subjects volunteering to participate in this
study will be compensated for their time according to the
terms specified by COMREC. Specifically, they will be
given the equivalent of USD 10 in Malawi Kwacha to
cover transport expenses when asked to visit the hospital
for study-related procedures when participating in the
specimen collection segment of the protocol, and add-
itional payment for their time when admitted in the
hospital for study-related procedures and for transport
expenses for the five follow up visits.
Parents or guardians will be given written, IRB-approved
informed consent forms in English or Chichewa, allowed
ample time to read the consent form, allowed to ask ques-
tions about the study, have their questions answered and
given time to decide if s/he would like their child to par-
ticipate in the study. The informed consent will be read
verbally in Chichewa to those who are unable to read.
This will be done in the presence of an impartial witness
who will also sign the consent form. After reading or lis-
tening, the potential participant is asked to sign the in-
formed consent form. For those who cannot write, a
thumbprint will be placed on the form with the signature
of the witness and date. After obtaining informed consent,
participants will be given a signed copy of the informed
consent document and assigned a screening identification
number.
Risk/benefit
This study is primarily a longitudinal observational
study. The main risks to the subject will be during speci-
men collection of blood, stool, induced sputum, and NP
swabs. Good phlebotomy practices will be performed
during blood draws, to minimize the risk to the subject.
Both stool and NP swab collection are noninvasive pro-
cedures, routinely performed by study team members
and are of minimal inconvenience for the participant.
Induced sputum collection is a standard method of speci-
men collection for investigating respiratory Cryptosporidium
species infections, and is a much less invasive technique
than other airway sampling techniques such as bronchos-
copy. Sputum induction is viewed as a safe and tolerable
procedure among children with respiratory issues such as
asthma, with few or minor transient adverse effects, such as
sore throat. Studies have evaluated sputum induction among
pediatric patients who have severe or very severe pneumo-
nia. In > 1000 procedures performed in children with severe
pneumonia admitted to Kilifi District Hospital in Kenya,
only 1 serious adverse event occurred (a child with a known
seizure disorder had a brief convulsion during the adminis-
tration of hypertonic saline; the procedure was stopped and
the child recovered without sequelae [9]. Of 108 children en-
rolled into the pilot study in New Caledonia, none had an
adverse event sufficiently severe to require increased oxygen
therapy or nebulization or that led to termination of the pro-
cedure [9]. The Pneumonia Etiology Research in Child
Health (PERCH) conducted induced sputum on all enrolled
children between 1 and 59months of age at 5 African sites.
Induced sputum was successfully obtained on the vast
majority of children at all study sites and with the correct
training and resources was regarded as relatively straightfor-
ward and safe [10].
For this study, appropriate training and resources will
be provided to ensure safety of the subjects. We will
use the same contraindications as detailed in PERCH,
even though their study was focused on severe and very
severe pneumonia; we expect the majority of our en-
rolled patients to have diarrhoeal issues first and fore-
most, with any respiratory involvement expected to be
minor. We have been provided space in a well venti-
lated room in the Pediatric Research Ward for the con-
duct of this procedure, which will be stocked with an
emergency tray. Subjects will be monitored closely for
expected AEs during this study, and appropriate clinical
responses made if they occur. If recruitment is ex-
panded to include health clinics in Blantyre district, this
would be for the purpose of identifying subjects who
would then be referred to QECH for consent and speci-
men collection.
There is no direct benefit to subjects in this study
anticipated. Research on children and HIV infected
adults is justified by the burden of diarrhoeal and re-
spiratory tract infection in these populations. These
data will inform ongoing management strategies, and the
study participants will stand to benefit from the research
findings. It is hoped that better understanding of the role of
respiratory cryptosporidiosis in pediatric diarrheal disease
will inform development of therapeutics. Cryptosporidium
is an important cause of morbidity and mortality in mal-
nourished young children in the developing world and
persons with HIV infection. No effective treatments are
currently available for these populations. If an effective drug
could be found, that would be of great benefit to society.
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The principal benefit of this study is indirect, potential
benefit to society. However, patients will incur no cost for
participation in this study. Financial reimbursement will be
provided according to existing Malawi national research
guidelines.
Dissemination of results
Results will be presented to the QECH Department of
Pediatrics research meeting, and may be presented at
local/regional/international conferences and published in
a peer-reviewed journal.
Discussion
It is widely accepted that the gastrointestinal tract is
the principal site for cryptosporidium infection and dis-
ease. Apart from inhalation or contact with fomites,
respiratory infection may result from aspiration of
intestinal contents in patients with diarrheal disease or
via hematogenous spread through the intestinal vascu-
lature [6, 7]. It is unclear however, if initial infection in
patients with diarrheal disease occurs first in the
respiratory tract with subsequent spread to the gut or
vice versa. This study is specifically designed to address
this important question.
Study status
The study began recruitment in February 2019. At the
beginning of May 2019, 52 patients had been screened
with 14 patients PCR positive for cryptosporidium in
stool or sputum, a higher than expected recruitment
return at this stage of the study. We attribute this to
higher local prevalence of cryptosporidium (27.8%) com-
pared to other studies of cryptosporidium in children
(12.5–13.8%) [7, 11]. We expect a drop-off in screening
and recruitment as the rainy season ends with a resur-
gence in the next rainy season.
Participant safety
Fifty-one of the fifty-two enrolled participants have
undergone induced sputum collection. None had con-
traindications to the procedure at initial contact. No
adverse events or severe adverse events have been de-
tected or reported so far. A sub study evaluating safety
of induced sputum collection in Malawian children is
also being conducted. This will further add to evidence
on safety of induced sputum collection and optimum
follow up time after the procedure, data essential to
adoption of induced sputum collection in non-research
settings (public hospitals).
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